News

Candida auris is an emerging pathogen with a high level of resistance to standard anti-fungal treatments. It is a causative agent of candidiasis, which when systemic (i.e. within the bloodstream) can result in high levels of mortality. The US CDC released guidance last year on the reporting, diagnosis, treatment and control of C.auris. On the 16th February, […]

Leading Biodecontamination experts Bioquell warmly welcomes the latest publication by the HSE highlighting the timescale for hydrogen peroxide-based biocides to be compliant. The HSE Biocides e-Bulletin 22 September 2016 is entitled ‘Active Substance Approval Reminder’ and summarises all of the key dates for the evaluation of hydrogen peroxide in Product Types 1, 2, 3, 4, […]

A multi-national vaccine manufacturer approached Bioquell in order to perform a Biodecontamination within its FDA approved facility. The facility itself, some 5,500 cubic meters, was treated as a single Biodecontamination enclosure with the entire process completed within 30 hours. After a successful deployment of the project,the customer contacted Bioquell wishing to establish an industry leading […]

The latest generation isolator was installed at the National Institute for Bioprocessing Research and Training (NIBRT) based in Dublin, Ireland, this February. The Bioquell QUBE, a flexible aseptic workstation, is now up and running to assist with continual professional development at this leading institute for the life sciences industry. From order to installation, it only […]

A team from St Jude’s Hospital in Memphis, Tennessee have identified a genetic mutation within a VRE bacteria that appears to confer wide ranging antibiotic tolerance, particularly in a biofilm presentation. Published in January’s edition of mBIO (American Society for Microbiology) the research findings came about due to an extremely difficult case of bacteraemia in a 6 […]